Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04981795 · ClinicalTrials.gov registry record

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

A clinical trial of Diffuse Large B Cell Lymphoma, sponsored by Incyte Corporation.

Recruiting
Registry status
100
Enrollment target
20
Study locations

NCT04981795 is a study of Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 100 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04981795, a study of Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Incyte Corporation.

RECRUITING
Registry status
100 participants
Enrollment target
20
Study locations

Study Summary

The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.

Conditions Studied

Diffuse Large B Cell Lymphoma

Interventions

  • DRUG Tafasitamab

Study Locations (20)

North Carolina

  • Levine Cancer Institute - Charlotte
  • VA Medical Center - Durham - Durham
  • Leo Jenkins Cancer Center/ECU School of Medicine - Greenville

Ohio

  • Mercy Medical Center - Canton
  • Ohio Health Marion Area Physicians - Marion
  • Tri County Hematology & Oncology Associates, Inc - Massillon

Alabama

  • Alabama Oncology - Birmingham
  • Clearview Cancer Institute - Huntsville

Iowa

  • McFarland Clinic P.C. - Ames
  • Mission Cancer and Blood - Des Moines

Michigan

  • University of Michigan Comprehensive Cancer Center Michigan Medicine - Ann Arbor
  • Henry Ford Health System - Detroit

New Jersey

  • Morristown Medical Center - Morristown
  • Rutgers Cancer Institute of New Jersey - New Brunswick

California

  • University of California, Irvine Medical Center - Orange

Louisiana

  • Tulane Cancer Center - New Orleans

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-09-20
Est. Completion 2026-08-31

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04981795

The ClinicalTrials.gov registry entry for NCT04981795 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (54% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Tafasitamab is the first listed.

NCT04981795 reports 20 study locations spanning 12 distinct geographic areas - top geographies include North Carolina, Ohio, Alabama.

Frequently Asked Questions

What is clinical trial NCT04981795 about?

NCT04981795 is a clinical study titled "realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL". The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combin...

What is the current status of trial NCT04981795?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2021-09-20. Estimated completion is 2026-08-31.

What conditions does trial NCT04981795 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.

What interventions are being tested in trial NCT04981795?

The interventions under investigation include: Tafasitamab (DRUG).

Who is sponsoring clinical trial NCT04981795?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04981795 being conducted?

This trial has 20 study locations across Alabama, California, Iowa, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.